Keyword: University of California San Francisco
James Pennington joined AzurRx BioPharma as CMO as the company aims to launch a phase 2 trial of its lead candidate in cystic fibrosis this year.
The latest in biotech research includes a new way to grow human heart muscle and uncovering a genetic abnormality at the root of ALS and dementia.
Broad Institute scientists have created an RNA-editing method that makes reversible changes to DNA possible.
The past week brought discoveries related to tumor metastasis, the virulence of a superbug, and breast cancer risk.
A "blunted" version of CRISPR can be used to identify gene regulators in the genome and help unravel autoimmune disease.
UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
The director of UCSF's Cardiovascular Research Institute—Shaun Coughlin, M.D., Ph.D.—has joined the ranks of senior academics heading to drugmaker Novartis.
Anti-CRISPR proteins may be the key to preventing harmful side effects from off-target editing.
Most research aimed at finding an HIV cure is focused on wiping out the virus from immune cells, but a new discovery suggests a different approach is in order.
Numares launched its noninvasive urine test for kidney rejection, the first to use a metabolic biomarker network rather than just one.